Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by Defense World Staff on May 17th, 2023

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Rating) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.25.

Several brokerages have recently commented on CLBT. TheStreet downgraded Cellebrite DI from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Needham & Company LLC increased their price objective on Cellebrite DI from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, March 14th.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors have recently modified their holdings of the business. State Street Corp grew its holdings in Cellebrite DI by 23.5% during the first quarter. State Street Corp now owns 220,334 shares of the company’s stock valued at $1,342,000 after purchasing an additional 41,904 shares during the period. Geode Capital Management LLC grew its holdings in Cellebrite DI by 1.8% during the first quarter. Geode Capital Management LLC now owns 119,990 shares of the company’s stock valued at $731,000 after purchasing an additional 2,115 shares during the period. Renaissance Technologies LLC grew its holdings in Cellebrite DI by 475.9% during the first quarter. Renaissance Technologies LLC now owns 76,600 shares of the company’s stock valued at $466,000 after purchasing an additional 63,300 shares during the period. State of Tennessee Treasury Department bought a new position in Cellebrite DI during the first quarter valued at $48,000. Finally, BlackRock Inc. grew its holdings in Cellebrite DI by 43.7% during the first quarter. BlackRock Inc. now owns 480,017 shares of the company’s stock valued at $2,923,000 after purchasing an additional 146,057 shares during the period. 21.66% of the stock is owned by institutional investors.

Cellebrite DI Stock Down 2.0 %

Shares of Cellebrite DI stock opened at $5.40 on Wednesday. The company has a market cap of $1.02 billion, a PE ratio of 41.54, a price-to-earnings-growth ratio of 0.93 and a beta of 1.16. Cellebrite DI has a 52 week low of $3.80 and a 52 week high of $6.22. The business has a 50 day moving average price of $5.67 and a 200-day moving average price of $5.14.

Cellebrite DI (NASDAQ:CLBT – Get Rating) last issued its quarterly earnings data on Wednesday, February 15th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $74.02 million during the quarter, compared to the consensus estimate of $74.78 million. Cellebrite DI had a return on equity of 34.28% and a net margin of 44.63%. As a group, research analysts anticipate that Cellebrite DI will post 0.17 EPS for the current year.

Cellebrite DI Company Profile

(Get Rating)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.